Clinical trials: Double-blind Randomized Controlled Study
Autism Spectrum Disorder
Effect of Increasing Total Antioxidant Capacity in Autism Spectrum Disorder
This double-blind, randomized, controlled trial (RCT) has the aim to evaluating the effectiveness of increasing Total Antioxidant Capacity (TAC) as add-on intervention in two cohorts of patients with Autism Spectrum Disorder…
- Trial name
- TACASD (NCT06623227)
- Testing
- Vitamin E and C
- Where
- Indonesia
- Volunteers
- 50 people
- Sponsor
- Rinvil Renaldi
Asthma
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma
This is a randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare 2 dose levels of budesonide/albuterol BDA MDI (PT027) to its components budesonide BD MDI (PT008) and albuterol AS MDI (PT007)…
- Trial name
- DENALI (NCT03847896)
- Testing
- Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg
- Where
- 129 sites in United States, Argentina and 5 more
- Volunteers
- 1,001 people
- Sponsor
- Bond Avillion 2 Development LP
Autism Spectrum Disorder
pBFS Guided Precision Neuromodulation Treatment for ASD
This study aims to evaluate the neuromodulation (i.e., iTBS) effectiveness for treating autism spectrum disorder (ASD) by targeting at the pBFS-guided executive function brain network or social brain network.
- Trial name
- NCT05735262
- Testing
- active iTBS
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changping Laboratory
Cystic Fibrosis
Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease
The purpose of this trial is to evaluate the safety and effectiveness of a one dose strength of denufosol compared to placebo in patients with mild CF lung disease.
- Trial name
- NCT00357279
- Testing
- denufosol tetrasodium (INS37217) Inhalation Solution
- Volunteers
- 352 people
- Sponsor
- Merck Sharp & Dohme LLC
Phosphomannomutase 2 Deficiency, PMM2-CDG
A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
This study is evaluating the safety, effectiveness, and how the body absorbs, distributes, and eliminates GLM101, for participants with PMM2-CDG, including children, adolescents, and adults.
- Trial name
- NCT06892288
- Testing
- GLM101 (Part A, Double-blind), GLM101 (Part B, Open-label)
- Where
- 15 sites in United States, Belgium and 8 more
- Volunteers
- 50 people
- Sponsor
- Glycomine, Inc.
Acne Vulgaris
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
- Trial name
- NCT04321070
- Testing
- Clindamycin Phosphate, Clindamycin Phosphate RLD
- Where
- United States
- Volunteers
- 550 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Charcot-Marie-Tooth Disease Type 1A
Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
The purpose of this study is to determine whether PXT3003 is effective and safe in the treatment of Charcot-Marie-Tooth disease - Type 1 A (CMT1A).
- Trial name
- PLEO-CMT (NCT02579759)
- Testing
- PXT3003 dose 1, PXT3003 dose 2
- Where
- 30 sites in United States, Belgium and 6 more
- Volunteers
- 323 people
- Sponsor
- Pharnext S.C.A.
Cystic Fibrosis
Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients?
The purpose of this study is to investigate the effect of a nasal instillation of Vardenafil on nasal potential difference in cystic fibrosis patients homozygous for the F508del mutation
- Trial name
- NCT01002534
- Testing
- Vardenafil
- Where
- Belgium
- Volunteers
- 5 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
The primary objective of the study was to demonstrate the efficacy of dupilumab as a monotherapy in participants ≥12 years to <18 years of age with moderate-to-severe atopic dermatitis (AD).
- Conditions
- Moderate-to-Severe Atopic Dermatitis, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin, Diseases Genetic, Genetic
- Trial name
- NCT03054428
- Testing
- Dupilumab
- Where
- 45 sites in United States, Canada
- Volunteers
- 251 people
- Sponsor
- Regeneron Pharmaceuticals
Common Cold
Mucinex Exploratory Cold Study
This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo.
- Trial name
- NCT01046136
- Testing
- guaifenesin (Mucinex)
- Where
- United States
- Volunteers
- 378 people
- Sponsor
- Reckitt Benckiser Inc.
Bronchial Asthma
Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects
A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of MG-ZG122 Humanized Monoclonal Antibody Injection in Asthma Subjects, with Dosing Every 12 or 24 Weeks for 48 Weeks
- Trial name
- NCT07054034
- Testing
- MG-ZG122 Humanized Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Alport Syndrome, Metformin
Treatment With Metformin in Chinese Children With Alport Syndrome
This single-center, prospective, double-blind randomized placebo-controlled trial will evaluate the efficacy and safety of metformin in Chinese children with Alport syndrome who have received (and continue to receive)) ACEi/ARB.
- Trial name
- NCT05655728
- Testing
- Metformin
- Volunteers
- 78 people
- Sponsor
- Peking University First Hospital
Primary Hypercholesterolemia
Pediatric Study to Evaluate the Efficacy and Safety of Ezetimibe Monotherapy in Children With Primary Hypercholesterolemia (P05522)
The purpose of this study is to determine the effect of ezetimibe 10 mg/day compared to placebo on the reduction of low-density lipoprotein cholesterol (LDL-C) from baseline to 12 weeks of treatment in children >=6 to <=10 years…
- Trial name
- NCT00867165
- Testing
- ezetimibe
- Volunteers
- 138 people
- Sponsor
- Organon and Co
Attention Deficit Hyperactivity Disorder (ADHD)
Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
The purpose of this study is to evaluate the efficacy and safety of SHP465 at 6.25 mg in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children aged 6-12 years.
- Trial name
- NCT03325881
- Testing
- SHP465
- Where
- 41 sites in United States
- Volunteers
- 89 people
- Sponsor
- Shire
Bronchial Asthma
Antiepileptic Drug Carbamazepine in Treatment of Bronchial Asthma
The purpose of this study was evaluation the efficacy of antiepileptic drug carbamazepine in the treatment of mild-to-severe bronchial asthma.
- Trial name
- NCT00207428
- Testing
- Carbamazepine
- Volunteers
- 65 people
- Sponsor
- Centre of Chinese Medicine, Georgia
Eosinophilic Esophagitis
Budesonide for Eosinophilic Esophagitis
Eosinophilic Esophagitis (EE) is a chronic, T-helper 2 cell (TH2) - type inflammatory disorder of the esophagus with a rapidly increasing prevalence.
- Trial name
- BEE (NCT00271349)
- Testing
- Budesonide
- Where
- Switzerland
- Volunteers
- 28 people
- Sponsor
- Swiss EE Study Group
ATIII Deficiency
Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery
The purpose of this study is to test whether the administration of ATIII during the intra-operative period results in improved anticoagulation for cardiopulmonary bypass (CPB) and an attenuation of the activation of the…
- Trial name
- NCT02103114
- Testing
- Anti-thrombin III
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Duke University
Areata Alopecia, Alopecia
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age.
- Conditions
- Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases
- Trial name
- BRAVE-AA-PEDS (NCT05723198)
- Testing
- Baricitinib
- Where
- 127 sites in United States, Argentina and 10 more
- Volunteers
- 595 people
- Sponsor
- Eli Lilly and Company
Migraine
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and adolescents ≥ 6 to <18 years with episodic migraine.
- Trial name
- NCT05156398
- Testing
- Rimegepant
- Where
- 93 sites in United States, Canada and 5 more
- Volunteers
- 640 people
- Sponsor
- Pfizer
Duchenne Muscular Dystrophy
A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
This is a Phase 3, double-blind, placebo-controlled study with the primary objective of evaluating the efficacy of a single IV infusion of SGT-003 in pediatric ambulant male participants with DMD.
- Trial name
- NCT07160634
- Testing
- SGT-003
- Where
- 7 sites in United States, Australia and 1 more
- Volunteers
- 80 people
- Sponsor
- Solid Biosciences Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.